Endpoint Health blog · Dec 2024
The company highlighted a podcast interview featuring co-founder and CSO Diego Rey discussing Endpoint Health’s mission to bring lifesaving targeted therapies to critically ill patients.
Precision-first therapies
Public company, workplace, funding, and market signals
Endpoint Health is a precision-first biotechnology/therapeutics company focused on immune-driven critical and chronic illness. It combines therapeutics, companion diagnostics, and AI to personalize treatment and develop targeted therapies, especially for sepsis, ARDS, rheumatoid arthritis, and IBD.
Primary product
Precision-first therapeutics platform combining companion diagnostics and AI with targeted therapies for immune-driven diseases.
Founded
2018
Headquarters
Palo Alto, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Precision therapeutics / precision medicine
Offices
0 jobs at Endpoint Health
Check back later for new openings
Business model
Stage
Series A
Total raised
$64.1M
Latest round
Series A · Jun 2022
Latest amount
$52M
Leadership
Co-Founder and CEO
Co-Founder and COO
Co-Founder and Chief Scientific Officer
Ransi Somaratne, M.D.
Chief Medical Officer
Jeff Osborn
Co-Founder and Chief Technology Officer
David Leonard
COO & Head of Corporate Development
Kristen Taylor Meadows
Vice President, Discovery & Translational Science
Akbar Khan
Vice President, Clinical Operations
Julie Friedman
Vice President, Therapeutic Operations & Program Management
Pamela H.
Vice President of Finance
Public materials present a mission-driven, science-heavy culture centered on precision medicine, cross-functional collaboration across therapeutics/diagnostics/AI, and partnerships with hospitals and biopharma companies.
Pricing
Primarily B2B collaboration/licensing and clinical-development partnership model; public materials do not disclose standard subscription or list pricing.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$1M-$10M (public LinkedIn estimate; ~US$5.6M annual revenue shown in profile snippets)
Estimated monthly visits
1.2K
Traffic estimate as of Jun 2026
Endpoint Health blog · Dec 2024
The company highlighted a podcast interview featuring co-founder and CSO Diego Rey discussing Endpoint Health’s mission to bring lifesaving targeted therapies to critically ill patients.
Business Wire · Sep 2022
Endpoint Health named biotech veteran Ransi Somaratne as its first CMO to lead clinical strategy and drug-development programs across its precision-immunology pipeline.
Business Wire · Jun 2022
The company closed $52M in equity and debt financing, with investors including Mayfield, Humboldt Fund, AME Cloud Ventures, Boom Capital, Alix Ventures, Yaya Capital, Wireframe Ventures, The Venture Collective, HCX Ventures, and GHIC.
Business Wire · Feb 2022
Endpoint Health reported retrospective analyses in SHOCK suggesting immune-state gene-expression subtyping may identify septic-shock patients with different corticosteroid response and mortality outcomes.
Business Wire · Feb 2022
Endpoint Health and Grifols agreed to develop and commercialize Antithrombin III for sepsis, with Grifols providing up to $25M to support clinical development and the companies jointly funding manufacturing expansion after FDA approval.